Guidelines on post-exposure prophylaxis for measles. June 2019 by unknown
  
 
 
 
 
 
 
 
 
Guidelines on Post-Exposure 
Prophylaxis for measles 
June 2019 
 
Guidelines for Post-Exposure Prophylaxis for Measles 
 
 
2 
 
 
About Public Health England 
Public Health England exists to protect and improve the nation’s health and wellbeing, 
and reduce health inequalities. We do this through world-leading science, knowledge  
and intelligence, advocacy, partnerships and the delivery of specialist public health 
services. We are an executive agency of the Department of Health and Social Care, 
and a distinct delivery organisation with operational autonomy. We provide 
government, local government, the NHS, Parliament, industry and the public with 
evidence-based professional, scientific and delivery expertise and support. 
 
 
 
 
Public Health England 
Wellington House  
133-155 Waterloo Road 
London SE1 8UG 
Tel: 020 7654 8000 
www.gov.uk/phe   
Twitter: @PHE_uk  
Facebook: www.facebook.com/PublicHealthEngland  
 
Prepared by: Jamie Lopez Bernal, Gayatri Amirthalingam, Kevin Brown, Olivier le 
Polain, Mary Ramsay 
For queries relating to this document, please contact: Immunisation.lead@phe.gov.uk 
Telephone 0208 200 4000 
 
 
© Crown copyright 2019 
You may re-use this information (excluding logos) free of charge in any format or 
medium, under the terms of the Open Government Licence v3.0. To view this licence, 
visit OGL. Where we have identified any third party copyright information you will need 
to obtain permission from the copyright holders concerned. 
 
Published June 2019     
PHE publications     PHE supports the UN 
gateway number: GW-492    Sustainable Development Goals 
 
 
Guidelines on Post-Exposure Prophylaxis for measles 
 
3 
 
 
Contents 
About Public Health England 2 
Changes from the previous guidelines 4 
1. Overview 5 
2. Recommendations 6 
2.1 Immunosuppressed contacts 6 
2.1.1 Assessing susceptibility 6 
2.1.2 Management of immunosuppressed contacts 10 
2.2 Pregnant women 12 
2.2.1 Assessing susceptibility 12 
2.2.2 Management of pregnant contacts 12 
2.3 Infants 13 
2.4 Post-exposure prophylaxis following inadvertent vaccination with measles  
containing vaccine 14 
3. Dosage and administration of immunoglobulins 16 
3.1 Immunosuppressed patients 16 
3.2 Immunocompetent infants and pregnant women 16 
3.3 Issuing HNIG from the Rabies and Immunoglobulin Services (RIgS) at  
PHE Colindale 17 
3.4 In hours service at PHE Colindale 17 
3.5 Out of hours service at PHE Colindale 17 
4. Appendix 18 
4.1 Human Normal Immunoglobulin (HNIG) 18 
4.2 Measles mumps and rubella (MMR) vaccination 19 
4.3 Population susceptibility by age 20 
5. References 22 
 
 
  
 
 
 
Guidelines on Post-Exposure Prophylaxis for measles 
 
4 
 
 
Changes from the previous guidelines 
June 2019 
New section on inadvertent vaccination with MMR in immunosuppressed individuals. 
  
Update to doses of Human Normal Immunoglobulins following changes to vial sizes. 
  
Updated logistics for ordering and issuing Human Normal Immunoglobulins from the 
Rabies and Immunoglobulins service at PHE Colindale. 
 
August 2017 
The 2017 PEP guidelines updated the classification of immunosuppressed individuals 
(Groups A and B) and incorporate additional groups including individuals receiving 
newer immunosuppressive treatments such as biological therapies. 
 
Recommendations for the post exposure management of infant contacts have been 
updated. Infants under 6 months of age who have had close contact with a likely or 
confirmed measles case should be offered HNIG without assessing maternal immune 
status. This reflects the fact that the majority of UK born pregnant women are protected 
through vaccination rather than natural exposure and therefore have lower levels of 
measles antibodies. As a result, their infants will become susceptible at a younger age. 
 
Updated recommendations on the dose and mode of administration of 
immunoglobulins are summarised. Subcutaneous infusions are not considered practical 
for immunosuppressed individuals and so intravenous immunoglobulin (IVIG) is the 
recommended product to be used for post-exposure treatment. IVIG is not sourced 
from PHE but should be available through NHS hospital pharmacies. 
 
A new section has been included detailing the logistics of ordering Human Normal 
Immunoglobulins (HNIG) from the Rabies and Immunoglobulins (RIgS) service at PHE 
Colindale and provides information on the service provided both in and out of hours. 
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1. Overview 
Post-exposure prophylaxis (PEP) for measles has historically relied on use of normal 
immunoglobulin or measles vaccination of vulnerable contacts. However, the 
effectiveness of post exposure prophylaxis is limited and achieving high coverage with 
2 doses of measles- mumps-rubella (MMR) vaccine in the general population remains 
the optimal way to protect individuals. 
 
Despite this, because of the high risk of serious complications, contact tracing around 
reported measles cases should prioritise the identification of immunosuppressed 
individuals, followed by other vulnerable contacts (pregnant women and infants). The 
risk assessment for each identified contact will depend on their exposure risk and their 
likely susceptibility. For immunosuppressed contacts, an appropriate assessment of the 
nature and level of immunosuppression is central to a decision about PEP. 
 
These guidelines describe the rationale for PEP and update the recommendations, 
including dosage and timing. Further details about the risk assessment of vulnerable 
contacts can be found in the PHE National measles guidelines. 
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2. Recommendations 
In order to inform the decision to recommend post exposure prophylaxis, a local risk 
assessment should be undertaken to determine the likelihood of measles in the index 
case and the level of potential exposure of the vulnerable contacts. If the index case is 
laboratory confirmed, epidemiologically confirmed or considered likely to be measles by 
the local Health Protection Team (HPT), then the need for post exposure prophylaxis 
should be urgently addressed. Detailed information on the level and nature of exposure 
can be found in the PHE National Measles Guidelines. For each identified contact, the 
decision to offer PEP is based on the level and timing of exposure and susceptibility to 
measles. 
 
2.1 Immunosuppressed contacts 
2.1.1 Assessing susceptibility 
All immunosuppressed patients, as defined in chapter 6 of Immunisation against 
Infectious Disease, are at risk of severe measles and should be considered for 
intravenous immunoglobulin (IVIG) following any exposure to measles, which would 
need to be sourced from NHS hospital pharmacies.  
 
Prophylaxis will depend on the level of immunosuppression and the likelihood that the 
individual would have retained any pre-existing measles immunity. Many adults and 
older children with immunosuppression will have immunity due to past infection or 
vaccination. A prophylactic dose of immunoglobulin is unlikely to offer additional benefit 
to those who have detectable measles antibody using standard assays, as their 
antibody levels are probably significantly higher than those achieved after a 
prophylactic dose of immunoglobulin. 
 
This guidance is based largely on the assessment of individuals born and raised in the 
UK. In many other countries, a higher proportion of older adults are likely to be 
immune, and therefore following the UK algorithm would be a safe approach. 
Individuals who have come from a small number of countries where measles control 
has been achieved for a longer period than in the UK but who are not known to be fully 
vaccinated, however, may remain susceptible to an older age, and therefore testing is 
recommended. For example, individuals from the USA can generally only be assumed 
to be immune if fully vaccinated or born before 1957 (16). Similar considerations may 
apply for individuals from Canada and some Scandinavian countries. 
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People with severe defects of cell mediated immunity who are on regular IVIG 
replacement therapy do not require additional IVIG if the most recent dose was 
administered ≤3 weeks before exposure. Such individuals should be under the 
management of specialists in immunology and their need for replacement 
immunoglobulin therapy will have already been assessed by their immunologist (in line 
with advice disseminated through the UK Primary Immunodeficiency Network – UK 
PIN). 
 
All other individuals with immunosuppression who are not already on IVIG replacement 
therapy will require assessment at the time of an exposure. These individuals can be 
divided into 2 main groups (Groups A and B, see table 1), depending on their ability to 
maintain adequate antibody from past exposure or vaccination. 
 
Group A includes most patients with immunosuppression. 
 
These individuals should be able to develop and maintain adequate antibody from any 
prior successful vaccination or infection and can therefore be managed on the basis of 
evidence of protection at any time (prior to or since the diagnosis or treatment end). 
 
Patients in this group are likely to have developed an adequate response to vaccination 
or measles during childhood, and so it is recommended that their measles status is 
established prior to exposure (for example at the next out-patient appointment) so that 
post-exposure prophylaxis can be informed. 
 
For individuals born and raised abroad, where the history of measles may be less 
reliable, an individual risk assessment, ideally with rapid IgG antibody testing, is 
recommended. 
 
Group B includes individuals who are unlikely to have developed or maintained 
adequate antibody levels from past exposure or vaccination. 
 
This group can be further subdivided into B(i) individuals who can be managed based 
on a measles IgG test at the time of exposure or at any point since the end of 
treatment/diagnosis and B(ii) individuals who require IVIG following an exposure 
without the need for testing. In principle, individuals should be vaccinated or have had 
their immunity against measles tested after completing their treatment. 
 
Other individuals who do not meet the criteria for either Group A or B (for example 
HIV individuals with CD4 cell count>200/mm3, individuals receiving non-biological 
immune modulating drugs more than 3 months ago), should be considered as 
immunocompetent for the purposes of measles PEP. However, the decision on the use 
of IVIG in these groups may be taken on an individual basis by their specialist clinician.  
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Table 1 Classification of immunosuppression 
 
Group A - individuals who should develop and maintain adequate antibody from past exposure or vaccination 
Manage on basis 
of evidence of 
protection at any 
time (prior to or 
since the 
diagnosis or 
treatment end) 
• Patients receiving or within 6 months of completing immunosuppressive chemotherapy or 
radiotherapy for malignant disease, (other than those with ALL, a lymphoproliferative 
disorder or who have had HSCT) 
 
• Patients receiving systemic high-dose steroids, or who have received high dose steroids in 
the past 3 months. This would include: 
• Children who receive prednisolone, orally or rectally, at a daily dose (or its equivalent) of 
2mg/kg/day for at least one week, or 1mg/kg/day for one month. 
• Adults who receive short term high-dose corticosteroids (>40mg prednisolone per day or 
equivalent for more than 1 week) 
• Adults who receive long term lower dose corticosteroids (>20mg prednisolone per day or 
equivalent for more than 14 days) 
 
• Patients receiving high doses of non-biological oral immune modulating or other types of 
immunosuppressive drugs (alone or in combination with steroids) or who have received 
such therapy in the past 3 months. This would include: 
• Adults who receive methotrexate >25mg per week 
• Adults who receive azathioprine >3.0mg/kg/day or 
• Adults who receive 6-mercaptopurine >1.5mg/kg/day 
• Adults on cyclosporin, cyclophosphamide, leflunomide AND 
• Children (<16years) who receive any dose of the above drugs 
 
• Patients with human immunodeficiency virus (HIV) infection: i) >5 years of age and with a 
CD4 count <200 cells/μl (but without a diagnosis of AIDS) or ii) aged 5 years or less, with a 
CD4 count <500 cells/μl 
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Group B – individuals who lose or may not maintain adequate antibody levels from past exposure or vaccination 
B (i): Manage on 
basis of IgG 
obtained at the 
time of exposure 
(or since the 
diagnosis or 
treatment end) 
• Patients on or after completion of immunosuppressive chemotherapy for acute 
lymphoblastic leukaemia (ALL) 
• Patients with lymphoproliferative disorders (including haematological malignancies such as 
indolent lymphoma, leukaemia and plasma cell lymphoma). 
• Patients who have received a solid organ transplant 
• Patients more than 12 months after receiving a haematopoietic stem cell transplant (HSCT) 
• Patients receiving or within 6 months of completing biological therapies (alone or in 
combination with steroids). These include: 
monoclonal antibodies, for example alemtuzumab, ofatumumab and rituximab cytokine inhibitors, for 
example etanercept 
• Patients with a diagnosis of acquired immunodeficiency syndrome (AIDs) 
B (ii): Offer PEP 
regardless of 
status 
• Patients who have received a haematopoietic stem cell transplant (HSCT) within the past 12 
months 
• Patients with severe primary immunodeficiency* 
 
* this group may already be on long term IVIG replacement, which should provide equivalent protection to post exposure immunoglobulin.  
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2.1.2 Management of immunosuppressed contacts 
Group A 
 
Patients in group A should be urgently assessed for the need for IVIG. In the absence of 
a positive measles IgG test at any time (either prior to or since diagnosis /treatment or 
at the time of exposure), an assessment of susceptibility needs to be urgently 
undertaken based on the individual’s age, history of measles infection and vaccine 
status (table 2). 
 
For those requiring IgG testing, this should be done as soon as possible following 
exposure, given that the effectiveness of IVIG is likely to be higher when administered 
as early as possible following exposure (ideally within 72 hours) although it can be given 
up to 6 days following exposure. Urgent IgG testing is available in all regional public 
health laboratories, as well as many NHS laboratories. Most testing can be done the 
same day or out of hours. 
 
For immunosuppressed patients where exposure is recognised late or who are found to 
be antibody negative or equivocal between 6 and 18 days after exposure, discussion 
with the specialist caring for the individual should take place, and IVIG may be 
considered in order to attenuate infection. Where a second exposure occurs more than 
3 weeks after a first dose of immunoglobulin, a further dose of immunoglobulin will need 
to be considered. 
 
Group B 
 
For patients in group B (i) who have a documented positive measles IgG since 
diagnosis or treatment end, no IVIG is required. For all others in group B (i), urgent IgG 
testing should be conducted at the time of exposure. If it is not possible to test within 72 
hours of exposure, IVIG should be administered. 
 
For patients in group B (ii), IVIG should be provided regardless of previous measles IgG 
results and without the need for testing. 
 
For patients in group B, IVIG, if required, needs to be provided as soon as possible after 
exposure, ideally within 72 hours. 
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Table 2 Assessing evidence of protection in immunosuppressed contacts of measles 
 
Group A - individuals who should develop and maintain adequate antibody from past 
exposure or vaccination 
All ages Previous measles IgG positive Assume immune - do not give IVIG 
Born before 1970 Positive history of measles infection Assume immune - do not give IVIG 
No history of measles infection Rapid IgG test and issue if negative 
or equivocal 
If not possible to test within 6 days 
of exposure, assume immune 
- do not give IVIG 
Born between 1970 and 
1990 
Positive history of measles infection 
or vaccination 
Rapid IgG test and give IVIG if 
negative or equivocal 
If not possible to test within 6 days 
of exposure, assume immune 
- do not give IVIG 
No history of measles infection or 
vaccination 
Rapid IgG test and give if negative 
or equivocal 
If not possible to test within 6 
days of exposure, give IVIG 
Born after 1990 History of 2 measles containing 
vaccines 
Rapid IgG test and give if negative 
or equivocal 
If not possible to test within 6 days 
of exposure, assume immune 
- do not give IVIG 
History of one measles containing 
vaccine 
Rapid IgG test and give if negative 
or equivocal 
If not possible to test within 6 
days of exposure, give IVIG 
Unvaccinated Give IVIG 
Group B – individuals who lose or may not maintain adequate antibody levels from past 
exposure or vaccination 
Group B (i) Measles IgG positive since 
diagnosis or treatment completed 
Assume immune - do not issue 
No documentation or negative IgG 
since treatment or diagnosis 
Rapid IgG test and give IVIG if 
negative or equivocal 
If not possible to test within 3 
days of exposure, give IVIG 
Group B (ii) Offer IVIG regardless of status 
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2.2 Pregnant women 
2.2.1 Assessing susceptibility 
Seroprevalence studies have shown that less than 1% of individuals born before 1970 
and less than 10% born between 1970 and 1989 are antibody negative to measles. The 
low susceptibility is confirmed by few cases being confirmed in these age groups (data 
collated by PHE Immunisation Department at Colindale). Younger adults may have 
been naturally infected or vaccinated as children, with those born after 1978 being 
eligible for a second dose of measles-containing vaccine during the 1994 schools 
campaign. Routine measles IgG tests are likely to be specific and therefore have a high 
positive predictive value in adult populations (18). Individuals who tested IgG positive or 
equivocal for measles antibody on standard assays were all shown to have detectable 
measles antibody by neutralisation assays performed at the PHE Virus Reference 
Department (VRD). Therefore, HNIG is unlikely to offer additional benefit to individuals 
who are measles IgG positive or equivocal. As routine antibody tests lack sensitivity, 
however, a high proportion of those found to be measles IgG equivocal or negative are 
likely to be truly immune. Therefore, in older women (born before 1990) with a reliable 
history of measles infection, antibody testing is unnecessary and should be avoided. 
 
Individuals born after 1990 are unlikely to have been exposed to natural measles and 
will mainly have acquired immunity through vaccination. Around 90% of individuals 
respond to a single dose of measles-containing vaccine and around 95% will be 
protected following 2 doses. 
 
2.2.2 Management of pregnant contacts 
Recommendations for pregnant women are therefore based upon a combination of age, 
history and / or antibody testing. The current recommendations are summarised in 
Table 3. on the next page. 
 
The main aim of measles PEP for pregnant women is attenuation of disease and 
therefore HNIG can be used. This will be issued up to 6 days after exposure, allowing 
time for assessment of immunity status in most instances. Where a second exposure 
occurs more than 3 weeks after a first dose of immunoglobulin, a further dose may need 
to be considered. 
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Table 3: Assessment and treatment of pregnant women 
 
Pregnant women 
Born before 
1990 
History of measles 
infection  
Assume immune 
No history of measles 
infection  
Test and administer HNIG within 6 days 
only if measles antibody negative 
Born 1990 or 
later 
Two measles vaccines Assume immune 
One measles vaccine Test and administer HNIG within 6 days 
only if measles antibody negative 
Unvaccinated Test and administer HNIG if measles 
antibody negative. If not possible to test 
within 6 days of exposure, offer HNIG. 
 
 
2.3 Infants 
Most UK born mothers were born after routine measles vaccination was introduced, and 
are unlikely to have had exposure to natural measles. Among vaccinated mothers, the 
levels of transplacentally acquired antibodies tend to be low and to wane rapidly, 
generally in a few weeks after birth (1, 2). If mothers have had a history of measles, 
maternal antibodies may protect for longer, but recent evidence shows that passive 
maternal immunity is unlikely to confer effective protection later than a few months after 
birth (1, 2). All infants under 6 months old who have a significant exposure to measles 
should get HNIG due to the high likelihood of maternal antibodies interfering with the 
response to MMR vaccine. See table 4 
 
Infants aged 6 to 8 months who are household contacts of a case and therefore have a 
higher intensity exposure should be given HNIG due to the increased risk of more 
severe disease. Infants aged 6 to 8 months who have exposures in non- household 
settings are less likely to have the intensity of exposure to develop severe disease and 
so should receive MMR vaccine. Infants aged 9 months or older should receive MMR 
vaccine as response to MMR is improved at this age. Vaccine is also preferred in non-
household settings as it may protect against a tertiary wave of cases in that setting. 
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Table 4: Assessment and treatment of infants 
 
Infants 
Infants <6 
months 
Assume susceptible and administer HNIG, ideally within 72 hours but 
up to 6 days, regardless of maternal status 
Infants aged 
6-8 months 
For household exposure, 
administer HNIG, ideally 
within 72 hours but up to 
6 days if necessary 
For exposures outside of the household, 
administer MMR, ideally within 72 hours 
Infants ≥9 
months 
Administer MMR vaccine, ideally within 72 hours of exposure 
 
Where post-exposure vaccination is indicated (Table 4) MMR should ideally be given 
within 3 days of exposure. Offering HNIG between 3 and 6 days after exposure is 
unlikely to offer substantial additional benefit in immunocompetent infants. Where 
exposure is likely to be on-going (for example following a single case in a nursery or 
during a community outbreak), MMR offered beyond 3 days may provide protection 
from subsequent exposures.  
 
Due to interference from maternal antibody, the efficacy of a dose of vaccine provided 
between 6 – 11 months of age is lower than that provided at 12 -13 months (19), and 
therefore doses offered before 1 year of age should be discounted and children should 
be offered 2 doses of MMR vaccine according to the national schedule. All additional 
immunisations should be recorded in the red book and should be notified to the local 
Child Health Information System (CHIS). 
 
2.4 Post-exposure prophylaxis following inadvertent vaccination with measles 
containing vaccine 
Due to the potential for live attenuated vaccines to replicate and cause disease in 
immunosuppressed individuals, administration of MMR to an immunosuppressed 
individual should be risk assessed as a potential exposure to measles and managed as 
per these guidelines (section 2.2). The risk assessment should be undertaken in 
consultation with the clinician caring for the immunosuppressed patient; if the clinical 
assessment is that the patient is not sufficiently immunosuppressed and can tolerate the 
attenuated vaccine virus, IVIG is not required.  
 
Pregnant women do not require post-exposure prophylaxis if they are inadvertently 
given MMR. 
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PHE has undertaken surveillance of vaccination in pregnancy since 1981 and the data 
to date are reassuring with regards to maternal and infant outcomes, when MMR is 
given in pregnancy or shortly prior to pregnancy. However, these cases should be 
reported and followed up. Further information is available at: 
www.gov.uk/government/publications/vaccine-in-pregnancy-advice-for-pregnant-
women/mmr-measles-mumps-rubella-vaccine-advice-for-pregnant-women. 
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3. Dosage and administration of 
immunoglobulins 
PHE has performed plaque neutralisation testing of currently available immunoglobulin 
products manufactured by BPL and Baxalta and has received similar data from CSL 
Behring. Based on these results, and applying the protective per/kg dose established by 
Endo et al (7), the doses of intramuscular HNIG recommended in the past are not fully 
protective,(13) and therefore a fully protective dose cannot be realistically achieved 
using an intra-muscular injection (See Appendix 4 for more information). The following 
modified doses, allowing for the lowest levels of neutralising measles antibody observed 
in products available in the UK, are therefore recommended: 
 
3.1 Immunosuppressed patients 
For immunosuppressed individuals, the protective dose should be provided using 
intravenous immunoglobulin (IVIG). This is available through NHS hospital pharmacies 
and not from PHE stockholders. This would constitute a grey indication in the current 
National Demand Management plan (http://www.igd.nhs.uk/). 
 
Based on testing results of products from 3 manufacturers the mean content of measles 
antibody by plaque neutralisation varies from 4 to 34 IU/ml (80-330 IU/g) for IVIG. A 
minimum protective dose of approximately 11 IU/kg measles antibody should therefore 
be achievable using a dose of 0.15 g/kg of IVIG. 
 
3.2 Immunocompetent infants and pregnant women 
For immunocompetent infants and pregnant women, who are normally managed in the 
community where IVIG is not practical, intramuscular HNIG is recommended. Given the 
lower dose of measles antibody recommended, the aim of providing HNIG is to 
attenuate, rather than prevent, disease. The following intra-muscular doses are 
recommended. 
 
Pregnant women: approximately 3000 mg 
Infants: 0.6ml/kg up to a maximum of 1000mg 
 
Subgam® can be issued from PHE stockholders on request. Other HNIG products 
available in the NHS (including Cuvitru, Hizentra and Gammanorm) are available from 
local hospital pharmacies and have been shown to contain similar levels of measles 
antibody. 
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Subgam and Gammanorm can be administered via the intramuscular or subcutaneous 
route. Note that the current Subgam Summary of Product Characteristics (SPC) does 
not mention intramuscular administration. However, discussions with the manufacturer 
are ongoing to update the SPC to re-incorporate the intramuscular route of 
administration in line with previous SPCs. Cuvitru and Hizentra are currently only 
approved for subcutaneous administration. 
3.3 Issuing HNIG from the Rabies and Immunoglobulin Services (RIgS) at PHE 
Colindale 
HNIG (Subgam) can be issued by the Rabies and Immunoglobulin Service (RIgS) at 
PHE Colindale, and from a number of stockholders across the country, the list of which 
is available. 
3.4 In hours service at PHE Colindale 
For practical purposes, requests that are made Monday-Friday will be ordered through 
Movianto for delivery to arrive on the next working day. Requests received after 1pm 
cannot be ordered/requested until the next working day. Ordering of immunoglobulin on 
a Friday will only be possible if the delivery address is open on a Saturday. If this is not 
the case, a courier would need to be arranged or the issue would need to wait until the 
next working day. 
For urgent requests, stock can be issued from Colindale during work hours for providers 
to collect using a courier service, paid by the provider. The Colindale site is open for 
collection 24 hours a day, 7 days a week (see below). 
Alternatively, HNIG can be issued from the nearest stockholder. 
Further information on issuing of immunoglobulin is available at: 
www.gov.uk/government/publications/immunoglobulin-when-to-use/rabies-and-
immunoglobulin-rigs-changes-to-the-current-service 
3.5 Out of hours service at PHE Colindale 
PHE can issue products from Colindale between 2 and 3pm at weekends and bank 
holidays for the requestor to arrange collectionusing a courier. Therefore, for the 
majority of patients, arrangements should be made for collection and administration of 
the immunoglobulin the next day. 
Further information on issuing of immunoglobulin is available at: 
www.gov.uk/government/publications/immunoglobulin-when-to-use/rabies-and-
immunoglobulin-rigs-changes-to-the-current-service 
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4. Appendix 
4.1 Human Normal Immunoglobulin (HNIG) 
The effectiveness of intra-muscular (IM) HNIG for measles prophylaxis was first 
established in young children in the 1940s. Janeway et al. (3) published a controlled 
study in children which demonstrated the effectiveness of gamma globulin in preventing 
disease if administered to household contacts within 4-5 days of exposure. In this study, 
families of index cases with 2 or more susceptible household contacts were divided into 
2 groups; the groups were similar with respect to age and exposure history. The 
intervention group received intra-muscular human serum gamma globulin at a dose of 
2.5mls for children below 5 years and 5mls for children over 5 years. The attack rate in 
the control group was 43/46 (94%) compared to 18/62 (29%) in the intervention group; 
consistent with an efficacy of 69%. In addition, 17 of the 18 children who developed 
measles in the intervention group compared to only 2 of 43 in the control group had a 
mild disease suggesting that immunoglobulin can also modify clinical measles. 
 
Further uncontrolled studies in the USA (4, 5) confirmed the effectiveness of 
immunoglobulin as post-exposure prophylaxis against measles. In 1943, 891 
susceptible household contacts (mainly children) received intramuscular injections of 
between 0.5 and 5mls of human serum gamma globulin within 7 days of exposure. The 
attack rate was 96/237 (41%), 52/107 (49%) and 148/344 (43%) amongst children up to 
5 years of age, those aged 6-12 years and older children and adults respectively. All 
subjects experienced a mild infection. Within the same age range, increasing the dose 
from 2 to 5mls increased the probability of preventing measles from 66% to 80%, 
suggesting that the total dose of measles antibody given was important. In 1960, 38 
susceptible children received gamma globulin (within 24-48 hours from onset of rash in 
index case) during an outbreak in an institution for disabled male children. Nineteen 
(50%) did not develop any clinical signs of measles. 
 
In 1990, an observational study in the US found the protective efficacy of post exposure 
HNIG given within 6 days of exposure (assumed to be 4 days prior to rash onset in the 
index case), was estimated at only 8% (95% CI 0, 59%) (6) One reason for the low 
observed effectiveness at this time may be due to changes in the measles antibody 
content of HNIG. This hypothesis is supported by the only more recent study to 
investigate immunoglobulin as post-exposure prophylaxis (7), Endo et al (7) found that 
in 14 children who received immunoglobulin (at the Japanese recommended dose of 
0.33ml/kg) with a titre of < 16 IU/ml, 8 (57%) had clinically evident measles, whilst the 
13 individuals who received immunoglobulin with a titre of >40IU/ml were completely 
protected from disease. 
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There is currently no accepted minimum level of measles antibody required in HNIG in 
England and Wales. Human Normal Immunoglobulin (HNIG) is prepared from pooled 
plasma derived from blood donations (sourced from outside the UK due to the 
theoretical risk of transmission of variant CJD). Levels of measles antibody are lower in 
people with vaccine-induced rather than naturally acquired immunity(8), and antibody 
levels are lower in the absence of exposure to circulating measles(9). As the proportion 
of vaccinated donors has risen, and as control of measles has improved in most 
countries, there is likely to have been a concomitant decline in measles neutralising 
antibodies derived from their plasma. As the dose of measles antibody given in HNIG 
appears to be important in providing efficacy, (4, 7) it is likely that currently 
recommended products and doses are significantly less effective than observed in 
earlier studies. This explanation is also likely to apply to most of the studies cited in the 
2014 Cochrane review, which were mainly conducted before 1960 
(http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010056.pub2/full). In addition, 
most studies published to date have been conducted predominantly in young children. 
The appropriate dose of HNIG to provide sufficient antibody for adults exposed to 
measles in the UK has not been clearly established, and must therefore be extrapolated 
from studies in children. 
 
There is no consistent evidence regarding the efficacy of immunoglobulins provided 4-6 
days after exposure and its use is primarily to reduce severity of disease in vulnerable 
contacts. Therefore it is important to administer immunoglobulin to vulnerable contacts 
as soon as possible after exposure and ideally within the first 72 hours. 
 
4.2 Measles mumps and rubella (MMR) vaccination 
The evidence for the effectiveness of measles vaccine as post exposure prophylaxis is 
less well established, despite the current recommendation of use within 72 hours of 
exposure. Two early studies (10, 11) proposed that vaccine is effective in preventing 
secondary cases if given soon after exposure. In 1963, Watson (10) suggested 
prevention of clinical disease in family contacts from a single household when vaccine 
was administered one day after onset of rash in the index case. In the second study, 
protection amongst school contacts was suggested for up to 14 days after exposure. 
 
During the 1990 US measles epidemic however, the protective efficacy of post 
exposure vaccination given to household contacts aged 1-5 years within 3 days of rash 
onset in the primary case, was estimated at only 4% (95% CI 0, 36%). In a more recent 
report (12), MMR vaccine failed to protect any of 4 contacts when given within 4 days of 
exposure in a UK nursery setting. The lower observed effectiveness in practice is likely 
to be partly explained by the timing and nature of exposure. 
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Overall, the limited evidence suggests that MMR may prevent disease, or reduce its 
severity, when administered soon after exposure (within 72 hours). Beyond this period, 
MMR should protect individuals from future measles exposures and provide protection 
against mumps and rubella. Importantly, in outbreak-prone settings such as schools and 
nurseries, MMR should prevent tertiary transmission in those who have not already 
been significantly exposed. 
 
As neither immunoglobulin nor vaccine are fully effective in preventing measles, 
exposed individuals who receive post-exposure treatments will still be an infection 
control risk, for example in health care settings. Any rash illness within the 21 days 
following exposure (ie the maximum incubation period (13)) could be measles, although 
measles like symptoms can occur after vaccination. Oral fluid samples can be used to 
type the virus (ie vaccine or wild type) if taken within one week of onset. 
 
4.3 Population susceptibility by age 
In the absence of reliable information on the individual’s history of measles infection and 
vaccination status, an assessment of susceptibility should take into account the 
exposure to natural disease. For example, individuals who were born before 1970 and 
grew up in the UK are very likely to have had natural exposure to measles, and 
although measles vaccination was introduced in 1968, coverage remained low until the 
mid-1980s and endemic measles continued to circulate (13). Seroprevalence studies 
suggest that fewer than 1% of individuals born before 1970 are susceptible to measles 
(14). 
 
As vaccination coverage increased during the 1970s and 1980s, fewer individuals were 
exposed to circulating measles, and seroprevalence studies suggest that up to 10% of 
individuals born during that period are non-immune. Since 1990, relatively high 
vaccination coverage has resulted in little endemic measles circulation in the UK, with 
the exception of a few localised outbreaks. Individuals born in 1990 or after will 
therefore only be immune through vaccination, and if unvaccinated are highly likely to 
be susceptible. 
 
For individuals who were born and raised abroad, the assessment is more difficult. With 
the exception of the US, where a measles vaccine was introduced in 1963 and where 
the incidence of measles was on the decline in the 1960s, all other countries have had 
pre-vaccine endemic measles circulation until 1970, or later. Most adults from countries 
where measles control is poor or where vaccination was introduced later are likely to be 
immune, and following the guidelines for individuals born in the UK would therefore be a 
safe and conservative approach. 
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Information on defining the nature and level of exposure is summarized in the PHE 
National Measles Guidelines. This document focuses on the assessment of 
susceptibility for vulnerable contacts and the recommendations (dosage and timing) for 
immunoglobulin only. 
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